CommercialCoverageMedium impact
Enfuvirtide (Fuzeon) (CPB 0671, reviewed 2026-03-25)
Aetna·Infectious Disease, Internal Medicine, Pediatrics·Medical Policy
Effective date
Mar 25, 2026
We identified it
Aug 13, 2026
Summary
Aetna updated its Enfuvirtide (Fuzeon) medical policy (CPB 0671) effective 2026-03-25, clarifying coverage criteria for HIV-1 treatment in treatment-experienced patients with documented viremia, resistance, or intolerance. The policy explicitly excludes treatment-naïve patients and COVID-19 indications as experimental/investigational. Billing teams must verify prior authorization requirements and ensure claims include proper documentation of treatment history and virologic response.
Action Required
By 2026-03-25: Billing team must update claims submission procedures to reflect Aetna's coverage criteria for J1324 (Injection, enfuvirtide, 1 mg). (1) Implement prior authorization logic requiring verification that patient has viremia AND either: (a) 3+ months of prior antiretroviral therapy with at least one appropriate regimen, OR (b) documented resistance or intolerance to at least one appropriate regimen. (2) Update billing system to flag claims for treatment-naïve patients (ICD-10 B20 without documented treatment history) as non-covered/experimental and route for denial. (3) Ensure claims include documentation of virologic response (positive or stable) for continuation of therapy requests. (4) Block submission of J1324 claims with ICD-10 U07.1 (COVID-19) as these are explicitly non-covered. (5) Providers must document pediatric dosing compliance (2 mg/kg twice daily, max 90 mg twice daily for ages 6+ weighing ≥11 kg) for claims involving patients under 18. Claims submitted without adequate treatment history documentation or for excluded indications will be denied.